An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma

Trial Profile

An Open-label, Fixed-dose, Clinical Study of Quinacrine Safety and Efficacy in the Treatment of Advanced Renal Cell Carcinoma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs Mepacrine (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Cleveland BioLabs
  • Most Recent Events

    • 31 Jul 2015 Planned End Date changed from 1 Dec 2009 to 1 Jan 2008 as reported by ClinicalTrials.gov record.
    • 01 Feb 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top